How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad and the ugly ways.

How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad and the ugly ways. Expert Rev Pharmacoecon Outcomes Res. 2019 Dec 06;: Authors: Inotai A, Kaló Z Abstract Introduction: There is significant difference in utilisation of patented medicines in the EU, as pharmaceuticals at Western European price levels are usually not cost-effective in Central Eastern European (CEE) countries. The article reviews options to solve the 'financing gap' posed by the challenge of covering patented medicines from more restricted resources in countries with greater unmet medical need.Areas covered: Hidden volume restrictions to patented pharmaceuticals implemented by payers to facilitate financial sustainability may increase European inequity in patient access. Confidential price discounts and financial risk sharing agreements improve cost-effectiveness of pharmaceuticals with limited impact on the European floor price. Narrowing the eligible group of patients on the positive drug list can help to target the medicines to patients with potentially greater health benefit whilst reducing the budget impact. Pay-for-performance schemes can improve cost-effectiveness of pharmaceuticals with significant uncertainty or heterogeneity in the magnitude of added therapeutic value. Increased utilisation of off-patent pharmaceuticals can increase patient access through re-investing the savings from generi...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research